Gilead Sciences | GILD - صافي الدخل





صافي الدخل تغيير تاريخ
AbbVie USD 695M 1.12B 2026-03
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
ALKERMES USD -66.48M 115.82M 2026-03
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Amgen USD 1.82B 486M 2026-03
Biogen USD 319.5M 368.4M 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Coherus Biosciences USD -37.64M 2.11M 2025-12
Eli Lilly USD 7.4B 760M 2026-03
Gilead Sciences USD 2.02B 162M 2026-03
GlaxoSmithKline GBP 1.74B 1.1B 2026-03
Glaxosmithkline GBP 846.06M 1.87B 2025-12
Incyte USD 303.33M 4.05M 2026-03
J&J USD 5.24B 119M 2026-03
Merck USD -4.24B 7.2B 2026-03
Moderna USD -1.34B 517M 2026-03
Neurocrine Biosciences USD 197.9M 44.2M 2026-03
Novartis USD 3.16B 747M 2026-03
Pfizer USD 2.69B 4.34B 2026-03
PTC Therapeutics USD -2.81M 132.16M 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Sanofi EUR 1.61B 2.42B 2026-03
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
United Therapeutics USD 274.9M 89.4M 2026-03
Vertex Pharmaceuticals USD 1.03B 159.7M 2026-03